Stephen K. Doberstein
2018
In 2018, Stephen K. Doberstein earned a total compensation of $4.8M as Chief Research and Development Officer at Nektar Therapeutics, a 37% decrease compared to previous year.
Compensation breakdown
| Non-Equity Incentive Plan | $480,000 |
|---|---|
| Option Awards | $1,965,476 |
| Salary | $600,000 |
| Stock Awards | $1,748,824 |
| Other | $17,556 |
| Total | $4,811,856 |
Doberstein received $2M in option awards, accounting for 41% of the total pay in 2018.
Doberstein also received $480K in non-equity incentive plan, $600K in salary, $1.7M in stock awards and $17.6K in other compensation.
Rankings
In 2018, Stephen K. Doberstein's compensation ranked 2,131st out of 14,244 executives tracked by ExecPay. In other words, Doberstein earned more than 85.0% of executives.
| Classification | Ranking | Percentile |
|---|---|---|
All | 2,131 out of 14,244 | 85th |
Division Manufacturing | 770 out of 5,765 | 87th |
Major group Chemicals And Allied Products | 257 out of 2,128 | 88th |
Industry group Drugs | 205 out of 1,817 | 89th |
Industry Pharmaceutical Preparations | 158 out of 1,391 | 89th |
Source: SEC filing on April 30, 2019.
Doberstein's colleagues
We found four more compensation records of executives who worked with Stephen K. Doberstein at Nektar Therapeutics in 2018.
2018
Howard Robin
Nektar Therapeutics
Chief Executive Officer
2018
Jillian Thomsen
Nektar Therapeutics
Chief Accounting Officer
2018
Gil Labrucherie
Nektar Therapeutics
Chief Financial Officer
2018
Maninder Hora
Nektar Therapeutics